<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02295163</url>
  </required_header>
  <id_info>
    <org_study_id>NL46979.091.13</org_study_id>
    <nct_id>NCT02295163</nct_id>
  </id_info>
  <brief_title>Stellate Ganglion Block for Hot Flushes in Men Treated With ADT</brief_title>
  <official_title>Short-term Efficacy of Stellate Ganglion Block in Men to Reduce Hot Flushes Related to Androgen Deprivation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rijnstate Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rijnstate Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Androgen deprivation therapy (ADT) is widely used as standard therapy in the treatment of&#xD;
      locally advanced and metastatic prostate cancer. Hot flushes and night sweats are one of the&#xD;
      main side-effects of ADT. There are no successful and well-tolerable treatment options&#xD;
      available. A possible treatment for hot flushes is stellate-ganglion block (SGB), used as a&#xD;
      means of interrupting parts of the sympathetic nervous system involved in temperature&#xD;
      regulation.&#xD;
&#xD;
      Objective of this study:&#xD;
&#xD;
      To assess the short-term efficacy of stellate ganglion block on hot flush reduction versus&#xD;
      sham procedure&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Androgen deprivation therapy (ADT) is widely used as standard therapy in the treatment of&#xD;
      locally advanced and metastatic prostate cancer. Hot flushes and night sweats are one of the&#xD;
      main side-effects of ADT. There are no successful and well-tolerable treatment options&#xD;
      available. A possible treatment for hot flushes is stellate-ganglion block (SGB), used as a&#xD;
      means of interrupting parts of the sympathetic nervous system involved in temperature&#xD;
      regulation.&#xD;
&#xD;
      Objective of this study&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    no participants&#xD;
  </why_stopped>
  <start_date type="Actual">July 2014</start_date>
  <completion_date type="Actual">January 2021</completion_date>
  <primary_completion_date type="Actual">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hot flush score</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Sham procedure</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>injection of NACL 0,9% in the stellate ganglion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stellate ganglion block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>injection of Bupivacaine 0,5% in the stellate ganglion</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stellate ganglion block</intervention_name>
    <description>7 ml of 0.5% bupivacaine will subsequently be injected next to the stellate ganglion to produce a sympathetic block.</description>
    <arm_group_label>Stellate ganglion block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham procedure</intervention_name>
    <description>7 ml of 0.9 % sodium chloride will subsequently be injected next to the stellate ganglion</description>
    <arm_group_label>Sham procedure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male&#xD;
&#xD;
          -  Age: &gt;18 years&#xD;
&#xD;
          -  Mean daily flush frequency of 10 or more and a hot flush score of 15 or more&#xD;
&#xD;
          -  Treatment with ADT because of prostate cancer&#xD;
&#xD;
          -  Absence of any other cause of flushing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of medication that affects flushing: oestrogens, progestogens, clonidine,&#xD;
             naloxone, paroxetine, fluoxetine, venlafaxine, gabapentin, luteinizing&#xD;
             hormone-releasing hormone receptor antagonist&#xD;
&#xD;
          -  Still receiving chemotherapy of radiotherapy&#xD;
&#xD;
          -  Psychiatric disease&#xD;
&#xD;
          -  Any unstable concurrent disease&#xD;
&#xD;
          -  Allergic reactions against bupivacaine or contrast media.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>jw. kallewaard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rijnstate Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rijnstate Hospital</name>
      <address>
        <city>Arnhem</city>
        <state>Gelderland</state>
        <zip>6815 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 11, 2014</study_first_submitted>
  <study_first_submitted_qc>November 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2014</study_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rijnstate Hospital</investigator_affiliation>
    <investigator_full_name>Jan Willem Kallewaard phd</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Stellate ganglion block</keyword>
  <keyword>hot flushes</keyword>
  <keyword>androgen deprivation therapy</keyword>
  <keyword>prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Ganglion Cysts</mesh_term>
    <mesh_term>Hot Flashes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

